Metabolon, Inc. has entered into an agreement with InnVentis Ltd. to apply metabolomics in individuals with chronic inflammatory diseases, such as rheumatoid arthritis. InnVentis aims to bring together multi-omics technologies with clinical data and machine learning to enable precision medicine for these conditions.
Metabolomics is the study of small molecules called metabolites and is a powerful phenotyping technology for precision medicine. It measures changes in metabolite levels and maps them to the appropriate biochemical pathways to give clinicians a better understanding of health and the influences of genes, microbiome, diet, lifestyle and drug treatment.
Generating molecular maps of distinct health and disease states may enable treatment or even prevention of chronic inflammatory diseases, where therapeutic decision is currently based on trial and error. Treatment strategies often fail to manage the disease or adequately match patients with optimal therapy. Chronic arthritic diseases cost the U.S. an estimated $128 billion annually, and half the patients lose their ability to continue to work. Chronic inflammation is a major driver for almost all chronic debilitating diseases and subsequent death.
“We’re working with InnVentis to expand the knowledge we can apply toward chronic inflammatory diseases, starting with studies of rheumatoid arthritis,” said John Ryals, PhD, Metabolon CEO. “Our goal is to use our proprietary technology in conjunction with InnVentis’s platform to provide a more accurate health assessment of patients, as well as clinically useful information. Metabolomics may help answer key biological questions about these complex disorders and improve personalized treatment.”
The InnVentis platform combines data with cutting-edge algorithms to create actionable insights through cost-efficient sourcing of multi-omics and clinical analytics, use of machine learning, and stringent sample and data collection control.
“Metabolomics has proven to be a most powerful technology to identify specific subgroups of patients with chronic inflammatory diseases, and we are honored to work with Metabolon, the leader in the field,” said Thomas Wilckens, MD, CEO of InnVentis. “By combining metabolomics with other ‘omics that are ready for exponential scale, InnVentis aims to enable novel, real-time disease management for clinicians and patients. This will include drug responder identification upon first diagnosis, as well as drug dosing management, using a more comprehensive solution built on the Internet of Things (IoT).”